Low molecular weight heparin prevents activation of coagulation in a hypobaric environment

被引:20
作者
Bendz, B [1 ]
Sevre, K [1 ]
Andersen, TO [1 ]
Sandset, PM [1 ]
机构
[1] Univ Oslo, Ulleval Hosp, Haematol Res Lab, N-0407 Oslo, Norway
关键词
anti-activated factor X activity; hypobaric hypoxia; low molecular weight heparin; prothrombin fragments 1+2; thrombin-antithrombin complex; tissue factor pathway inhibitor; travel; thromboprophylaxis;
D O I
10.1097/00001721-200107000-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
It is commonly thought that people are at increased risk of venous thrombosis during air flights, but the magnitude of the risk is unknown. Suggested risk factors are hypobaric hypoxia, stasis, and dehydration. In a previous experimental study, we found immediate activation of coagulation as determined by the levels of prothrombin fragments 1 + 2 (F1+2) and thrombin-antithrombin complex (TAT) after rapid exposure to a hypobaric and hypoxic environment (76 kPa). The aim of the present study was to examine the ability of low molecular weight heparin (LMWH) to prevent such activation. Twelve healthy male volunteers were given 40 mg enoxaparin as a single subcutaneous injection 1 h prior to exposure from 96.3 to 76 kPa. We found no activation of coagulation as judged by F1+2 or TAT. Anti-activated factor X activity levels and release of tissue factor pathway inhibitor was normal. We conclude that high prophylactic doses of a LMWH most probably prevent activation of coagulation in a hypobaric environment. (C) 2001 Lippincott Williams & Wilkins.
引用
收藏
页码:371 / 374
页数:4
相关论文
共 18 条
[1]   Association between acute hypobaric hypoxia and activation of coagulation in human beings [J].
Bendz, B ;
Rostrup, M ;
Sevre, K ;
Andersen, TO ;
Sandset, PM .
LANCET, 2000, 356 (9242) :1657-1658
[2]   Dose-dependent release of endogenous tissue factor pathway inhibitor by different low molecular weight heparins [J].
Bendz, B ;
Andersen, TO ;
Sandset, PM .
BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (04) :343-348
[3]   A new sensitive chromogenic substrate assay of tissue factor pathway inhibitor type 1 [J].
Bendz, B ;
Andersen, TO ;
Sandset, PM .
THROMBOSIS RESEARCH, 2000, 97 (06) :463-472
[4]   Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement [J].
Bergqvist, D ;
Benoni, G ;
Bjorgell, O ;
Fredin, H ;
Hedlundh, U ;
Nicolas, S ;
Nilsson, P ;
Nylander, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (10) :696-700
[5]  
Colon V F, 1977, Med Times, V105, P52
[6]   ALTITUDE EXPOSURES DURING AIRCRAFT FLIGHT - FLYING HIGHER [J].
COTTRELL, JJ .
CHEST, 1988, 93 (01) :81-84
[7]   AIR-TRAVEL AND THROMBOTIC EPISODES - THE ECONOMY CLASS SYNDROME [J].
CRUICKSHANK, JM ;
GORLIN, R ;
JENNETT, B .
LANCET, 1988, 2 (8609) :497-498
[8]   Venous thromboembolism in association with prolonged air travel [J].
Eklof, B ;
Kistner, RL ;
Masuda, EM ;
Sonntag, BV ;
Wong, HP .
DERMATOLOGIC SURGERY, 1996, 22 (07) :637-641
[9]   Travel as a risk factor for venous thromboembolic disease - A case-control study [J].
Ferrari, E ;
Chevallier, T ;
Chapelier, A ;
Baudouy, M .
CHEST, 1999, 115 (02) :440-444
[10]  
HOFFMANN R, 1993, THROMB HAEMOSTASIS, V70, P712